Comparing Revenue Performance: ACADIA Pharmaceuticals Inc. or Novavax, Inc.?

ACADIA vs. Novavax: A Decade of Revenue Dynamics

__timestampACADIA Pharmaceuticals Inc.Novavax, Inc.
Wednesday, January 1, 201412000030659000
Thursday, January 1, 20156100036250000
Friday, January 1, 20161733100015353000
Sunday, January 1, 201712490100031176000
Monday, January 1, 201822380700034288000
Tuesday, January 1, 201933907600018662000
Wednesday, January 1, 2020441755000475598000
Friday, January 1, 20214841450001146290000
Saturday, January 1, 20225172350001598951000
Sunday, January 1, 2023726437000556382000
Loading chart...

Unlocking the unknown

Revenue Race: ACADIA Pharmaceuticals vs. Novavax

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's success. This chart compares the annual revenue performance of ACADIA Pharmaceuticals Inc. and Novavax, Inc. from 2014 to 2023. Over this period, ACADIA Pharmaceuticals demonstrated a steady upward trajectory, with revenue increasing by over 6,000% from 2014 to 2023. In contrast, Novavax experienced a more volatile journey, with a significant revenue spike in 2021, reaching its peak in 2022, before declining in 2023. This fluctuation highlights the impact of external factors, such as the COVID-19 pandemic, on Novavax's financial performance. By 2023, ACADIA's revenue surpassed Novavax's by approximately 30%, showcasing its consistent growth strategy. This comparison underscores the diverse challenges and opportunities faced by pharmaceutical companies in a dynamic market.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025